Lineage Cell Therapeutics, Inc. (LCTX)
USD 0.5
(0.93%)
USD 0.5
(0.93%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 101.01 Million USD | -18.31% |
| 2022 | 123.66 Million USD | -29.15% |
| 2021 | 174.54 Million USD | 61.69% |
| 2020 | 107.94 Million USD | -13.97% |
| 2019 | 125.47 Million USD | 23.43% |
| 2018 | 101.66 Million USD | -41.32% |
| 2017 | 173.24 Million USD | 21.51% |
| 2016 | 142.57 Million USD | 50.61% |
| 2015 | 94.66 Million USD | 26.38% |
| 2014 | 74.9 Million USD | 29.74% |
| 2013 | 57.72 Million USD | 94.06% |
| 2012 | 29.74 Million USD | -35.09% |
| 2011 | 45.82 Million USD | -13.97% |
| 2010 | 53.27 Million USD | 296.58% |
| 2009 | 13.43 Million USD | 1197.31% |
| 2008 | 1.03 Million USD | 491.35% |
| 2007 | 175.1 Thousand USD | -73.08% |
| 2006 | 650.5 Thousand USD | -66.79% |
| 2005 | 1.95 Million USD | 28.73% |
| 2004 | 1.52 Million USD | 42.0% |
| 2003 | 1.07 Million USD | -28.38% |
| 2002 | 1.49 Million USD | -22.94% |
| 2001 | 1.94 Million USD | 15.73% |
| 2000 | 1.67 Million USD | -70.46% |
| 1999 | 5.67 Million USD | 102.81% |
| 1998 | 2.8 Million USD | -66.27% |
| 1997 | 8.3 Million USD | 176.67% |
| 1996 | 3 Million USD | -16.67% |
| 1995 | 3.6 Million USD | -38.98% |
| 1994 | 5.9 Million USD | 68.57% |
| 1993 | 3.5 Million USD | -27.08% |
| 1992 | 4.8 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 108.48 Million USD | 7.39% |
| 2024 Q2 | 102.8 Million USD | -5.24% |
| 2023 Q2 | 111.68 Million USD | -1.34% |
| 2023 Q3 | 106.15 Million USD | -4.96% |
| 2023 FY | 101.01 Million USD | -18.31% |
| 2023 Q4 | 101.01 Million USD | -4.84% |
| 2023 Q1 | 113.2 Million USD | -8.46% |
| 2022 Q3 | 131.14 Million USD | -3.51% |
| 2022 FY | 123.66 Million USD | -29.15% |
| 2022 Q2 | 135.92 Million USD | -5.95% |
| 2022 Q1 | 144.52 Million USD | -17.2% |
| 2022 Q4 | 123.66 Million USD | -5.71% |
| 2021 FY | 174.54 Million USD | 61.69% |
| 2021 Q1 | 127.92 Million USD | 18.51% |
| 2021 Q4 | 174.54 Million USD | 33.03% |
| 2021 Q3 | 131.21 Million USD | -2.63% |
| 2021 Q2 | 134.75 Million USD | 5.34% |
| 2020 FY | 107.94 Million USD | -13.97% |
| 2020 Q3 | 103.09 Million USD | -8.02% |
| 2020 Q2 | 112.08 Million USD | -5.72% |
| 2020 Q1 | 118.88 Million USD | -5.26% |
| 2020 Q4 | 107.94 Million USD | 4.71% |
| 2019 Q3 | 132.97 Million USD | -12.34% |
| 2019 Q4 | 125.47 Million USD | -5.64% |
| 2019 Q2 | 151.69 Million USD | -17.43% |
| 2019 FY | 125.47 Million USD | 23.43% |
| 2019 Q1 | 183.71 Million USD | 80.72% |
| 2018 Q2 | 112.25 Million USD | 1.68% |
| 2018 Q4 | 101.66 Million USD | -42.26% |
| 2018 Q3 | 176.07 Million USD | 56.86% |
| 2018 Q1 | 110.39 Million USD | -36.28% |
| 2018 FY | 101.66 Million USD | -41.32% |
| 2017 Q1 | 205.21 Million USD | 43.94% |
| 2017 Q2 | 193.35 Million USD | -5.78% |
| 2017 Q3 | 221.86 Million USD | 14.75% |
| 2017 Q4 | 173.24 Million USD | -21.92% |
| 2017 FY | 173.24 Million USD | 21.51% |
| 2016 Q2 | 104.32 Million USD | 30.22% |
| 2016 FY | 142.57 Million USD | 50.61% |
| 2016 Q1 | 80.11 Million USD | -15.37% |
| 2016 Q3 | 147.57 Million USD | 41.45% |
| 2016 Q4 | 142.57 Million USD | -3.39% |
| 2015 Q4 | 94.66 Million USD | 23.16% |
| 2015 FY | 94.66 Million USD | 26.38% |
| 2015 Q1 | 69.7 Million USD | -6.94% |
| 2015 Q2 | 79.61 Million USD | 14.21% |
| 2015 Q3 | 76.85 Million USD | -3.46% |
| 2014 Q3 | 55.65 Million USD | -15.66% |
| 2014 FY | 74.9 Million USD | 29.74% |
| 2014 Q2 | 65.98 Million USD | 13.87% |
| 2014 Q1 | 57.94 Million USD | 0.38% |
| 2014 Q4 | 74.9 Million USD | 34.58% |
| 2013 Q4 | 57.72 Million USD | 87.11% |
| 2013 Q1 | 35.29 Million USD | 18.65% |
| 2013 Q2 | 39.89 Million USD | 13.02% |
| 2013 FY | 57.72 Million USD | 94.06% |
| 2013 Q3 | 30.85 Million USD | -22.66% |
| 2012 Q2 | 38.38 Million USD | -1.53% |
| 2012 Q4 | 29.74 Million USD | -9.5% |
| 2012 Q1 | 38.97 Million USD | -14.95% |
| 2012 FY | 29.74 Million USD | -35.09% |
| 2012 Q3 | 32.87 Million USD | -14.36% |
| 2011 FY | 45.82 Million USD | -13.97% |
| 2011 Q3 | 50.87 Million USD | -4.83% |
| 2011 Q4 | 45.82 Million USD | -9.92% |
| 2011 Q1 | 56.89 Million USD | 6.79% |
| 2011 Q2 | 53.45 Million USD | -6.03% |
| 2010 Q1 | 12.7 Million USD | -5.45% |
| 2010 FY | 53.27 Million USD | 296.58% |
| 2010 Q4 | 53.27 Million USD | 29.01% |
| 2010 Q3 | 41.29 Million USD | 20.93% |
| 2010 Q2 | 34.14 Million USD | 168.86% |
| 2009 Q4 | 13.43 Million USD | 44.97% |
| 2009 FY | 13.43 Million USD | 1197.31% |
| 2009 Q1 | 1.69 Million USD | 63.8% |
| 2009 Q2 | 5.78 Million USD | 241.0% |
| 2009 Q3 | 9.26 Million USD | 60.21% |
| 2008 Q2 | 609.47 Thousand USD | 8.5% |
| 2008 FY | 1.03 Million USD | 491.35% |
| 2008 Q1 | 561.72 Thousand USD | 220.8% |
| 2008 Q4 | 1.03 Million USD | 0.94% |
| 2008 Q3 | 1.02 Million USD | 68.31% |
| 2007 Q1 | 366.65 Thousand USD | -43.64% |
| 2007 FY | 175.1 Thousand USD | -73.08% |
| 2007 Q4 | 175.1 Thousand USD | 182.28% |
| 2007 Q3 | 62.03 Thousand USD | -69.08% |
| 2007 Q2 | 200.65 Thousand USD | -45.27% |
| 2006 Q1 | 1.76 Million USD | -10.03% |
| 2006 FY | 650.5 Thousand USD | -66.79% |
| 2006 Q4 | 650.5 Thousand USD | -22.8% |
| 2006 Q3 | 842.64 Thousand USD | -26.12% |
| 2006 Q2 | 1.14 Million USD | -35.28% |
| 2005 Q2 | 729.3 Thousand USD | -12.43% |
| 2005 FY | 1.95 Million USD | 28.73% |
| 2005 Q1 | 832.85 Thousand USD | -45.26% |
| 2005 Q4 | 1.95 Million USD | 244.27% |
| 2005 Q3 | 568.96 Thousand USD | -21.99% |
| 2004 FY | 1.52 Million USD | 42.0% |
| 2004 Q4 | 1.52 Million USD | -6.98% |
| 2004 Q3 | 1.63 Million USD | -24.29% |
| 2004 Q2 | 2.16 Million USD | -5.3% |
| 2004 Q1 | 2.28 Million USD | 112.9% |
| 2003 FY | 1.07 Million USD | -28.38% |
| 2003 Q2 | 806.93 Thousand USD | -43.18% |
| 2003 Q4 | 1.07 Million USD | -17.59% |
| 2003 Q1 | 1.42 Million USD | -5.07% |
| 2003 Q3 | 1.3 Million USD | 61.13% |
| 2002 FY | 1.49 Million USD | -22.94% |
| 2002 Q2 | 730.16 Thousand USD | -42.39% |
| 2002 Q1 | 1.26 Million USD | -34.71% |
| 2002 Q3 | 1.96 Million USD | 168.86% |
| 2002 Q4 | 1.49 Million USD | -23.79% |
| 2001 Q3 | 2.38 Million USD | 260.94% |
| 2001 Q1 | 890.43 Thousand USD | -46.92% |
| 2001 FY | 1.94 Million USD | 15.73% |
| 2001 Q4 | 1.94 Million USD | -18.56% |
| 2001 Q2 | 660.43 Thousand USD | -25.83% |
| 2000 Q3 | 2.31 Million USD | -17.61% |
| 2000 Q2 | 2.8 Million USD | -30.67% |
| 2000 Q1 | 4.05 Million USD | -28.66% |
| 2000 FY | 1.67 Million USD | -70.46% |
| 2000 Q4 | 1.67 Million USD | -27.51% |
| 1999 Q2 | 8.4 Million USD | -9.68% |
| 1999 Q3 | 7 Million USD | -16.67% |
| 1999 Q1 | 9.3 Million USD | 0.0% |
| 1999 Q4 | 5.67 Million USD | -18.88% |
| 1999 FY | 5.67 Million USD | 102.81% |
| 1998 Q2 | 4.6 Million USD | -17.86% |
| 1998 Q3 | 3.8 Million USD | -17.39% |
| 1998 Q1 | 5.6 Million USD | -16.42% |
| 1998 FY | 2.8 Million USD | -66.27% |
| 1997 Q3 | 7.7 Million USD | -7.23% |
| 1997 Q4 | 6.7 Million USD | -12.99% |
| 1997 FY | 8.3 Million USD | 176.67% |
| 1997 Q1 | 7.7 Million USD | 234.78% |
| 1997 Q2 | 8.3 Million USD | 7.79% |
| 1996 Q3 | 2.5 Million USD | -16.67% |
| 1996 FY | 3 Million USD | -16.67% |
| 1996 Q4 | 2.3 Million USD | -8.0% |
| 1996 Q2 | 3 Million USD | 0.0% |
| 1995 Q1 | 4.1 Million USD | -12.77% |
| 1995 Q2 | 3.6 Million USD | -12.2% |
| 1995 Q3 | 3 Million USD | -16.67% |
| 1995 FY | 3.6 Million USD | -38.98% |
| 1994 FY | 5.9 Million USD | 68.57% |
| 1994 Q3 | 5.5 Million USD | -6.78% |
| 1994 Q2 | 5.9 Million USD | -7.81% |
| 1994 Q1 | 6.4 Million USD | 128.57% |
| 1994 Q4 | 4.7 Million USD | -14.55% |
| 1993 FY | 3.5 Million USD | -27.08% |
| 1993 Q4 | 2.8 Million USD | -20.0% |
| 1993 Q3 | 3.5 Million USD | 0.0% |
| 1993 Q2 | 3.5 Million USD | -10.26% |
| 1993 Q1 | 3.9 Million USD | -4.88% |
| 1992 Q4 | 4.1 Million USD | -8.89% |
| 1992 Q3 | 4.5 Million USD | -6.25% |
| 1992 Q2 | 4.8 Million USD | -7.69% |
| 1992 Q1 | 5.2 Million USD | 0.0% |
| 1992 FY | 4.8 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 19.38 Million USD | -421.227% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -1661.14% |
| Armata Pharmaceuticals, Inc. | 109.96 Million USD | 8.134% |
| Actinium Pharmaceuticals, Inc. | 81.44 Million USD | -24.033% |
| Azitra, Inc. | 5.11 Million USD | -1874.768% |
| Can-Fite BioPharma Ltd. | 9.98 Million USD | -911.302% |
| Chromocell Therapeutics Corporation | 96.39 Thousand USD | -104701.278% |
| Calidi Biotherapeutics, Inc. | 10.01 Million USD | -908.274% |
| CEL-SCI Corporation | 30.52 Million USD | -230.903% |
| iBio, Inc. | 28.73 Million USD | -251.566% |
| MAIA Biotechnology, Inc. | 7.56 Million USD | -1235.02% |
| Matinas BioPharma Holdings, Inc. | 65.57 Million USD | -54.044% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -2210.798% |
| NovaBay Pharmaceuticals, Inc. | 9.03 Million USD | -1018.209% |
| NanoViricides, Inc. | 12.82 Million USD | -687.804% |
| Oragenics, Inc. | 4.96 Million USD | -1934.075% |
| BiomX Inc. | 58.15 Million USD | -73.703% |
| BiomX Inc. | 58.15 Million USD | -73.703% |
| Protalix BioTherapeutics, Inc. | 84.43 Million USD | -19.643% |
| Palatin Technologies, Inc. | 10.74 Million USD | -840.388% |
| Scorpius Holdings, Inc. | 51.03 Million USD | -97.93% |